(Reuters) - Mylan NV, which has come under fire for its drug pricing, said on Friday it would start selling a generic version of its life-saving EpiPen allergy treatment for $300 per two-pack, a more ...

The identical generic two-pack of EpiPens, expected to launch in several weeks, will have a list price of $300, which is half the list price of the brand product, but still significantly more than the ...

The CAFC also affirmed the district court’s ruling that Actelion failed to prove infringement by an equivalent, according to ipwatchdog.com. The report went on to say that Actelion further argued that ...

Mylan N.V. (NASDAQ: MYL) disclosed the launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar, in the United States. According ...

The first bellwether case scheduled to be tried in the Generic Pharmaceuticals Pricing antitrust litigation has been postponed after Mylan objected to an “apparent conflict of interest” involving the ...

NEW YORK, March 27 (Reuters) - Mylan Laboratories Inc. appeared set to have exclusive rights to sell generic versions of Pfizer Inc.'s Norvasc blood-pressure drug until at least April 13 after a U.S.

Generic drugmaker Mylan Pharmaceuticals Inc. has received FDA approval to begin shipping a generic version of a drug that treats gallstones. Ursodia USP is a bile acid that naturally occurs in the ...

(Reuters) - Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV, a move that leaves Pfizer with its more profitable innovative drugs, ...

PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday. Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the ...

The patent at play in the lawsuit expires in November of 2026. (Shutterstock) In its latest effort to defend against forthcoming Entresto copycats, Novartis is taking to U.S. federal court to allege ...

The US Food and Drug Administration (FDA) announced Thursday that it has denied Mylan’s petition that sought to block certain generic applications for Advair (fluticasone propionate and salmeterol).

Connecticut officials announced the settlement with Mylan on Thursday. It resolves allegations that the pharmaceutical ...